Pulmonary Hypertension
Congress Materials – CardioVascular Clinical Trialists (CVCT 2025)
2025 CardioVascular Clinical Trialists | Dec 8-10 | Washington, DC
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Dose rationale for UNISUS, an ongoing, event-driven, phase III superiority study evaluating macitentan 75mg vs 10mg in pulmonary arterial hypertension (PAH)
Dénes Csonka, Gurinderpal Doad, Juan José Pérez-Ruixo
UNISUS study design: an ongoing, event-driven, Phase 3 superiority study evaluating macitentan 75 mg versus 10 mg in patients with pulmonary arterial hypertension (PAH)
Vallerie V. McLaughlin, Yuichi Tamura, Marc Humbert, Arthur Backer, Neli Boyanova, Hilke Kracker, Cheryl Lassen, Anna Larbalestier, Lilian Sanna, Gurinderpal Doad, Ioana R. Preston, Marius Hoeper
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.